Onco-Innovations Achieves Kilogram-Scale Manufacturing Milestone for Lead Cancer Drug Candidate
Onco-Innovations Limited successfully produced nearly a kilogram of the B4 precursor for its ONC010 PNKP inhibitor, advancing toward clinical trials and scalable production.
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) announced the successful advancement of kilogram-scale manufacturing activities for the B4 precursor component used in the development of ONC010, the company’s lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology. This milestone, achieved through its chemistry, manufacturing and controls collaboration with Dalton Pharma Services, resulted in the production and isolation of approximately 952 grams of B4 material, supporting future formulation development, GMP production and planned clinical studies.
The manufacturing milestone strengthens Onco-Innovations’ integrated development strategy and supports the establishment of a scalable production process for future clinical supply. According to the company, this progress is critical for advancing ONC010 toward clinical trials and ultimately commercialization. The ability to produce kilogram-scale quantities of the precursor is a significant step in de-risking the supply chain and ensuring that the drug candidate can be manufactured consistently and cost-effectively at larger volumes.
In a separate announcement, Onco-Innovations also disclosed the engagement of InvestorBrandNetwork (IBN) to provide market awareness, corporate communications and digital media services through Sept. 30, 2026, or until budget exhaustion. The company will pay IBN an aggregate cash fee of US$76,500 for the services and intends to apply an unused US$80,000 balance returned from a prior market awareness engagement toward the consideration. This move suggests that Onco-Innovations is actively seeking to increase its visibility among investors and the broader financial community as it progresses its oncology pipeline.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. For more information, visit https://oncoinnovations.com/.
This development is particularly important because the ONC010 program targets PNKP, an enzyme involved in DNA repair that is often overexpressed in cancer cells. By inhibiting PNKP, the drug candidate aims to sensitize tumors to DNA-damaging therapies such as radiation and chemotherapy. The successful scale-up of the B4 precursor brings Onco-Innovations closer to clinical testing, which could eventually lead to more effective treatment options for patients with solid tumors. The full press release is available at https://ibn.fm/BbWHd.
BioMedWire (BMW) is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com.